アブストラクト | Angioedema results from the decreased degradation of vasoactive peptides such as substance P and bradykinin. In this study, we sought to clarify whether dipeptidyl peptidase-4 (DPP-4) and angiotensin-converting enzyme (ACE) inhibitors that suppress the degradation of substance P and bradykinin are involved in angioedema onset. We calculated information coefficients (ICs) by performing a disproportionality analysis to evaluate DPP-4/ACE inhibitor-induced angioedema using the Japanese Adverse Drug Event Report (JADER) database. No angioedema signals were detected for DPP-4 inhibitors; however, a signal was detected for ACE inhibitors (IC: 2.42, 95% confidence interval (CI): 2.19 to 2.65). Of the patients treated with DPP-4 inhibitors, four developed drug-induced angioedema in combination with ACE inhibitors, and all were taking vildagliptin. Signals were detected for enalapril (IC: 2.39, 95% CI: 2.06 to 2.71), imidapril (IC: 2.83, 95% CI: 2.38 to 3.27), lisinopril (IC: 2.28, 95% CI: 1.55 to 3.00), temocapril (IC: 1.35, 95% CI: 0.29 to 2.40), and trandolapril (IC: 1.57, 95% CI: 0.19 to 2.95). Both inhibitors inhibited the degradation of substance P and bradykinin and were thus expected to cause angioedema. However, no signal of angioedema was detected with the DPP-4 inhibitors, in contrast to some ACE inhibitors. This study found that ACE inhibitors and DPP-4 inhibitors, which inhibit the degradation of substance P and bradykinin, tended to have different effects on the onset of angioedema in clinical practice. |
ジャーナル名 | Journal of clinical medicine |
Pubmed追加日 | 2021/12/11 |
投稿者 | Noguchi, Yoshihiro; Murayama, Azusa; Esaki, Hiroki; Sugioka, Mayuko; Koyama, Aisa; Tachi, Tomoya; Teramachi, Hitomi |
組織名 | Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4,;Daigakunishi, Gifu-shi 501-1196, Japan.;Department of Pharmacy, Ichinomiya Municipal Hospital, 2-2-22 Bunkyou,;Ichinomiya-shi 491-8558, Japan. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34884209/ |